KDM2A Antibodies

Lysine-specific demethylase 2A (KDM2A)

Histone demethylase that especially demethylates'Lys- 36' of histone H3, thereby playing a central role in histone code. Preferentially demethylates dimethylated H3'Lys-36' residue while it has weak or no activity for mono- and tri-methylated H3'Lys- 36'.

May also recognize and bind to some phosphorylated proteins and encourage their ubiquitination and degradation. Required to keep the heterochromatic state.

Gene Information

Human
Gene Name:	KDM2A
Uniprot:	Q9Y2K7
Entrez:	22992

Family

Belongs to:
JHDM1 histone demethylase family

Alternative Names

[Histone-H3]-lysine-36 demethylase 1A; CXXC8F-box protein FBL7; CXXC-type zinc finger protein 8; FBL11DKFZp434M1735; FBL7F-box protein Lilina; F-box and leucine-rich repeat protein 11DKFZP434M1735; F-box protein FBL11; FBXL11FLJ46431; FLJ00115; JHDM1AF-box/LRR-repeat protein 11; JmjC domain-containing histone demethylation protein 1A; jumonji C domain-containing histone demethylase 1A; KIAA1004EC 1.14.11.27; LILINA; lysine (K)-specific demethylase 2A; lysine-specific demethylase 2A; SF-KDM2A

Molecular Weight

Mass (kDA):
132.793 kDA

Genomic Context

Human
Location:	11q13.2
Sequence:	11; NC_000011.10 (67119263..67258082)

Tissue Specificity

Widely expressed, with highest levels in brain, testis and ovary, followed by lung.

Subcellular Localizations

Nucleus, nucleoplasm. Punctate expression throughout the nucleoplasm and enriched in the perinucleolar region. Specifically nucleates at CpG islands where it's presence results in chromatin depleted in H3K36me2.

Diseases

• Malignant Neoplasms
• Neoplasms
• Cell Transformation, Neoplastic
• Leukemia, Myelocytic, Acute
• Myeloid Leukemia
• Lymphoma
• Genomic Instability
• Leukemia
• Metaplastic Cell Transformation
• Glioma
• Hematopoietic Neoplasms
• Refractory Carcinoma

• Malignant Neoplasm Of Lung
• Carcinoma
• Rheumatoid Arthritis
• T-cell Lymphoma
• High Pressure Neurological Syndrome
• Hematologic Neoplasms
• Leukemogenesis

Interacting Proteins

• RELA
• SKP1

Pathways

• Demethylation
• Methylation
• Histone Demethylation
• Histone Methylation
• Dna Methylation
• Cell Proliferation
• Mitosis
• Senescence
• Ribosome Biogenesis
• Protein Demethylation
• Gene Silencing
• Cellular Senescence
• Dna Repair

• Response To Starvation
• Localization
• Regulation Of Histone Methylation
• Replicative Senescence
• Response To Uv
• Translation
• Cell Death

PTMs

• Demethylation
• Methylation

• Reduction
• Hydroxylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KDM2A

Best Uses Of The KDM2A Marker

Biological assays use antibodies to detect the presence of KDM2A. These antibodies can be monoclonal, polyclonal, and react with the protein in a variety of animal samples. Boster Bio develops its KDM2A antibodies using rabbit and mouse. Lysinespecific demethylase 2A (2LSD2A), a key component of the histone-code, preferentially reduces H3'Lys-36%. It may also recognize phosphorylated and promote their degrading. This marker can be used to perform biological assays that provide valuable information about cells' heterochromatic state.

KDM2A Tracker

The KDM2A Marker is expressed in all tissues, but in particular, its overexpression can antagonize the senescence of embryonic fibroblasts, promote somatic reprogramming, and prevent apoptosis of apical papilla stem cells. A recent study by Xu et al. KDM2A was found to be a regulator of TGF-b signaling pathways.

This gene is part of the JMJD family. It consists of the Jumonji Cdomain and the LRR-AMN1 Zylinder structure. It plays a crucial role in the methylation of mono and dimethylated himtone H3, which can affect chromosome structures and gene expression. It is vital in the regulation of cell proliferation, gene transcription, and chromosome structures. Here are the top uses of KDM2A.

Multiple studies have shown that KDM2A is involved in the progression and spread of cervical cancer. It also promotes cervical cancer cells' invasion and growth. KDM2A was found to be less expressed in prostate cancer tumors than in normal tissues. The heterogeneity of the disease, as well as the different sample sizes used in different studies may explain the diversity of the results.

The KDM2A gene marker is being increasingly used for the diagnosis of ccRCC. Its involvement during the initiation gives us a whole new perspective on how ccRCC is developed. KDM2A is best used in cancer research. Its identification could serve as a biomarker of the disease. It could be used to treat the disease if further research is done.

The expression of KDM2A regulates the expression of several clock genes. It also plays a key role in DNA repair as well as the regulation and maintenance of the circadian rhythm. It also helps to recruit the MRE11 complex at the injury site where it interacts and induces repair. It facilitates HP1a recruitment, which promotes H3K9me deposition.

A study of patients with ccRCC and lysine-specific methylase 2A found that KDM2A expression was correlated with a variety of clinicopathological characteristics. KDM2A expression in cancer cells was associated with a higher risk of patient death. Investigators also used knockdown strategies to identify genes related to KDM2A.

Biological assays

A RNAi assay is a useful tool that allows molecular characterization KDM2A of human cancer cells. This assay detects KDM2A expression by co-transfecting the target molecule with the corresponding mRNA. Boster Bio KDM2A acts as the target gene for miR-302a in this assay. This assay shows how miR-302a binds and inhibits KDM2A's activity. KDM2A is also co-expressed by miR-302a within 293 T cells. After cotransfection of the transgene and miR-302a, the activity of luciferase was measured using a Dual Luciferase Reporter Gene Assay System Promega.

The assay is done using the cDNA clone XR5–Cre-Phosphatase. In order to quantify protein expression, Boster Bio KDM2A biological assays include a radio-immunoprecipitation assay containing bicinchoninic acid and an appropriate quantitative kit. The extracted protein was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel, electro-transferred onto polyvinylidene fluoride membranes, blocked with 5% bovine serum albumin, and probed with antibodies to KDM2A, JAG1, and GAPDH.

After cloning NC-mimetics, the human miR-17-5p binding locations were synthesized in pYr/MirTarget. Tianyi Huiyuan Co. Ltd. produced mutants containing mutations within the mir-17-5p bound site. These mutations inhibited the expression of KDM2A genes.

Boster Bio KDM2A biological samples were used to determine if KDM2A is a target for JAG1 cancer. This enzyme increased JAG1 levels in breast cancer using RTQPCR. In a second study, overexpression of JAG1 increased JAG1 expression. KDM2A may be beneficial to glioma patients.

High-affinity primary antibodies

An antibody that binds a specific substance is called a high-affinity primary antibody. It is usually determined by calculating the equilibrium dissociation constant for bimolecular interactions. Because affinity binding is reversible and the rate at which antibodies bind to ligands is proportional the concentrations of both reactants. A lower KD value is indicative of a higher affinity for the given ligand.

We used three antibodies to immunoprecipitate KDM2A (R0K0 nuclear extract) in this study. Bethyl Laboratories (A301-475A) recognized both KDM2A in its full length and KDM2ASF in its short form. The N-terminal antibody failed to recognize the nucleosome and the latter antibody was more effective.

Another study showed that HP1 isoforms stimulate H3K9me3 nucleosome association with KDM2A. This interaction was also confirmed through immunoblotting using HP1a and HP1b as well as GST. These nucleosomes are specifically targeted for binding by the KDM2A antigen. In this study, the KDM2A marker was used to identify H3K9me3 nucleosomes.

The generation of autoreactive primary IgM can be limited by the lack of IgD. The loss IgD can cause a delayed transition between primary autoreactive antibody responses and secondary antigen specific antibody responses. In addition, IgD-deficient mice have a prolonged autoimmune disease. They do not produce protective IgG and IgM, resulting in decreased protection and immunity.

High-affinity primary antibodies produced using the KDM2A markers were previously difficult for antigen to be separated. High affinity antibodies are also difficult to extract from the affinity columns. It may also be necessary for the antigen to be removed using harsh or denatured methods. These methods can be very efficient for certain applications. They are increasingly becoming an important tool for research.

The immunostaining process uses nano-Secondaries. They are monovalent secondary antibody that binds with a high degree of affinity to IgGs. These antibodies are 10x smaller than traditional secondary antibodies. Nano-Secondaries offer better tissue penetration and reduce the distance between the epitopes and the label because of their small size.